ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update
ReShape Lifesciences, Inc. (RSLS)
US:NASDAQ Investor Relations:
ir.enteromedics.com
Company Research
Source: GlobeNewswire
Revenue Increased 16.6% in the Third Quarter of 2024 Over the Second Quarter, Representing the Third Sequential Quarter of Growth, and 6.4% Compared to the Same Period in 2023 Significant Reduction in Overall Operating Expenses of 40.6% in the First Nine Months of 2024 Compared to the First Nine Months of 2023 Entered into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys Conference Call to be Held at 4:30 pm ET Today, November 14, 2024 IRVINE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the third quarter ended September 30, 2024 and provided a corporate strategic update. Third Quarter 2024 and Subsequent Highlights November: Revenue increased for the third consecutive quarter and over the prior year despite continued pressures from nationwide marketing and ado
Show less
Read more
Impact Snapshot
Event Time:
RSLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RSLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RSLS alerts
High impacting ReShape Lifesciences, Inc. news events
Weekly update
A roundup of the hottest topics
RSLS
News
- ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate UpdateGlobeNewswire
- ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX [Yahoo! Finance]Yahoo! Finance
- ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEXGlobeNewswire
- ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California’s Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape’s Proprietary Diabetes Bloc-GlobeNewswire
RSLS
Sec Filings
- 11/14/24 - Form 8-K
- 11/14/24 - Form 10-Q
- 10/17/24 - Form 8-K
- RSLS's page on the SEC website